Worth reading
9Immaterial
Scored from 2 of 3 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
17.73
¥100 million (estimated proceeds)Wording
Avoiding a definitive answer
How definitive the wording is.What was corrected and how
A subsequent correction by the company to the contents of an already published filing.
Original disclosure
The number of days elapsed cannot be calculated because the original disclosure date is unknown.
This correction2026-10-13
Impact on Business Performance (the company’s explanation)
We expect the impact on the earnings forecast for the fiscal year ending December 2026 to be limited.
| Item | Details |
|---|---|
| Impact on Business Performance | We expect the impact on the earnings forecast for the fiscal year ending December 2026 to be limited. |
Items this document does not state (5)
Disclosure subject to correctionOriginal disclosure dateLocation of correctionDetails of correctionReason for correction
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To secure in advance the development and research expenses for the company's pipeline, including animal studies and investigator-initiated clinical trials, thereby advancing drug discovery and development smoothly and steadily and contributing to an increase in corporate value over the medium to long term.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.